Wolfe Research lowers Honeywell stock price target on aerospace weakness By Investing.com

Honeywell's Q2 EPS guidance of $2.35 to $2.45 came in below Wolfe Research's $2.46 estimate and the Street at $2.56, while Q1 revenue of $9.14 billion also missed expectations despite EPS of $2.45 beating consensus. Wolfe lowered its price target to $281 from $296, citing softer aerospace margin expansion, supply-chain constraints, and a $100 million to $150 million Middle East headwind in Process. The upcoming June 29 aerospace spinoff and 2026 recast guidance add complexity, but the tone is more cautious than alarming.

Analysis

The market is starting to price HON less as a steady industrial compounder and more as a messy transition story: near-term guidance misses, a temporary geopolitics hit to Process, and execution friction around aerospace supply chains are outweighing the longer-dated spin benefits. The key second-order effect is that a weaker Honeywell near term can actually improve the relative appeal of the post-spin pieces, because investors will eventually separate stranded-cost noise from core automation and aerospace earnings power. That said, the timing matters: the next 1-2 quarters are likely to be dominated by margin pressure and estimate cuts, so multiple expansion is hard to justify until the market sees cleaner standalone reporting.

The most important hidden variable is aerospace recovery quality, not just volume. If production ramps while supply constraints persist, HON can show top-line improvement without full margin leverage, which tends to disappoint a stock already de-rated on expectations of faster expansion. In other words, the path to upside is delayed by 2-3 quarters unless supplier bottlenecks clear faster than management is signaling; if they do, the surprise could be meaningful because backlog provides operating leverage once conversion normalizes.

The contrarian angle is that the spin and asset monetization optionality may be underappreciated in a risk-off tape. A cleaner automation company plus embedded value from Quantinuum/pension surplus creates a floor that could become visible once the market stops anchoring on the legacy consolidated EPS. The better way to express the view is likely relative value: HON can underperform on headline guide cuts while still being attractive versus lower-quality industrials with less balance-sheet optionality and no breakup catalyst.

Key Decisions for Investors

• Short HON into the next 2-6 weeks as a post-guidance de-rating trade; use the stock's failure to reclaim prior support as confirmation, with a target of another 5-8% downside if estimates keep drifting lower.
• Pair trade: long RTX or GE Aerospace vs short HON for the next 1-2 quarters; the thesis is that standalone aerospace exposures with cleaner execution should capture the re-rating while HON remains stuck with stranded-cost and supply-chain noise.
• For longer-horizon accounts, buy HON post-spin weakness on a 3-6 month basis if the stock discounts the automation business below peer multiples; upside comes from eventual separation of the conglomerate discount and monetization optionality.
• Use call spreads on HON only after evidence of aerospace margin inflection and supplier normalization; before that, upside is capped by near-term guide risk and headline volatility.
• If Process segment geopolitics intensify and the stock sells off further, look for a tactical bounce trade only after the market fully prices the $100M-$150M drag; the risk/reward improves once the move is no longer incremental.